Gala Therapeutics Receives CE Mark for its Minimally Invasive RheOx™ System for Chronic Bronchitis - BioSpace

Gala Therapeutics Receives CE Mark for its Minimally Invasive RheOx™ System for Chronic Bronchitis  BioSpace

Published: Sep 04, 2019. First-of-its-kind RheOx device designed to reduce mucus-producing cells and improve quality of life. MENLO PARK, Calif., Sept.



Comments

Popular Posts

Children's Cold Medicine Guide - Verywell Health